Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

Gynecologic Oncology

Volumn 127, Issue 2, 2012, Pages 362-366

  McCann, Georgia A ^a   Smith, Blair ^a   Backes, Floor J ^a   Rath, Kellie ^a   Chacko, Simi ^a   Salani, Ritu ^a   Eisenhauer, Eric ^a   Fowler, Jeffrey M ^a   Cohn, David E ^a   O'Malley, David M ^a  

^a M210 Starling Loving Hall ^*  (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Biologic therapy; Ovarian cancer; Recurrent ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN; VELIPARIB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETREATMENT; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84867398359     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.001     Document Type: Article

References (17)

1. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
2. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
3. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 2007 5165 5171
4. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 2012 Jun 10 2039 2045
5. A.E. Guppy, and G.J. Rustin CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 5 2002 437 443
6. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
7. P.V. Dickson, J.B. Hamner, T.L. Sims, C.H. Fraga, C.Y. Ng, and S. Rajasekeran Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin Cancer Res 13 13 2007 3942 3950
8. K. Shitara, M. Munakata, O. Muto, and Y. Sakata Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report Jpn J Clin Oncol 38 7 2008 493 496
9. B.W. Kang, T.W. Kim, J.L. Lee, M.H. Ryu, H.M. Chang, and C.S. Yu Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis Med Oncol 26 1 2009 32 37
10. H.X. Chen, M. Mooney, M. Boron, D. Vena, K. Mosby, and L. Grochow Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301 J Clin Oncol 24 21 2006 3354 3360
11. A. Grothey, M.M. Sugrue, D.M. Purdie, W. Dong, D. Sargent, and E. Hedrick Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 33 2008 5326 5334
12. C. Gridelli, J. Bennouna, J. de Castro, A.M. Dingemans, F. Griesinger, and F. Grossi Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial Clin Lung Cancer 12 6 2011 407 411
13. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
14. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 2006 4699 4707
15. D.S. Alberts, P.Y. Liu, S.P. Wilczynski, M.C. Clouser, A.M. Lopez, and D.P. Michelin Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) Gynecol Oncol 108 1 2008 90 94
16. M.E. van der Burg, F.B. Lammes, and J. Verweij The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary Surg Gynecol Obstet 176 4 1993 310 314
17. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J Clin Oncol 29 10 2011 1247 1251